NCT06906640Recruiting
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 2) (IRIS-CKD)
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 212 (estimated)
- First submitted
- 21 Feb 2025
- Start date
- 28 Oct 2025
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Duke University
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT06906640
What you commit to
- Study type: Interventional
- Planned participants: 212
- From 28 Oct 2025 to the primary completion date, 1 Apr 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- (CKD Management)
- Type 1 diabetes
- Most recent eGFR \<20 ml/min/1.73 m2
- Prior kidney transplant
- Autosomal dominant polycystic kidney disease (ADPKD)
- Active pregnancy or plans for conception within 1 year
Who the study is looking for
- (CKD Management)
- Adults with type 2 diabetes (T2D)
- Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)
- Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):
- UACR \>300 mg/g or
- eGFR \<45 ml/min/1.73 m2 or
- UACR ≥30 mg/g with eGFR \<60 ml/min/1.73 m2
- Receiving \<100% GDMT at baseline. For patients with UACR \<30 mg/g, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi/ARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Recruiting |
| University of Alabama Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
| Essentia Institute of Rural Health Coordinator of this site? Confirm its status | Duluth | United States | Recruiting |
| Duke University Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
| Houston Methodist Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| Orlando Health Coordinator of this site? Confirm its status | St. Petersburg | United States | Recruiting |
| Baylor Scott & White Coordinator of this site? Confirm its status | Temple | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.